Login to Your Account



PharmaFocus

Facing Steepest Patent Cliff, Lilly's Outlook Gets Lowered

By Marie Powers
Staff Writer

Wednesday, October 24, 2012

On the eve of reporting third-quarter earnings, Eli Lilly and Co. confronted a storm warning from Fitch Ratings, which affirmed the big pharma's ratings – including the issuer default rating (IDR) – at "A" but lowered its outlook on the company from "stable" to "negative."

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription